Try our Advanced Search for more refined results
Harden Manufacturing Corporation v. Pfizer, Inc. et al
Case Number:
1:04-cv-10981
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Abeyta Nelson
- Adams Fietz
- Anderson Hemmat
- Andrews DeValerio
- Axelrod Firm
- Aylstock Witkin
- Bainbridge Mims
- Baker Botts
- Baker Wotring
- Baron & Budd
- Barry McTiernan
- Beasley Allen
- Bellas & Wachowski
- Berman & Simmons
- Berman Tabacco
- Bernstein Liebhard
- Betts Patterson
- Blank Rome
- Boies Schiller
- Boone Law Firm
- Boone Law Firm PA
- Bradley Arant
- Breslin & Breslin
- Brown & Crouppen
- Brown Rudnick
- Bruno & Bruno LLP
- Bullard & Wangerin
- Clifford Law Offices
- Climaco Wilcox
- Cohen & Malad
- Cohen Milstein
- Cohn Lifland
- Cooper Elliott
- Cunard Law Firm
- Cuneo Gilbert
- Davis Polk
- Dechert LLP
- Dugan Law Firm
- Eldridge Cooper
- Faegre Drinker
- Fayard & Honeycutt
- Fears Nachawati
- Fennemore Craig
- Fibich Leebron
- Finkelstein & Partners
- Flaherty Sensabaugh
- Foley & Lardner
- Garan Lucow
- Gilman Law LLP
- Girards Law Firm
- Goldenberg Heller
- Goldstein Buckley
- Goodell DeVries
- Good Schneider
- Gordon Rees
- Groves & Verona
- Habush Habush
- Hagens Berman
- Halloran & Sage
- Hassett & Donnelly
- Heninger Garrison
- Heyl Royster
- Hobbie & DeCarlo
- Hutchings Barsamian
- Jacoby & Meyers LLP
- Jenner Law
- Johnson Pope
- Jones Day
- Kaplan Fox
- Kessler Topaz
- Ketterer Browne
- Kirkland & Ellis
- Kitrick Lewis
- Latham & Watkins
- Law Offices of Manuel H. Miller
- Lieff Cabraser
- Lowe Mobley
- Lowenstein Sandler
- Lowey Dannenberg
- Manatt Phelps
- Mayer Brown
- Mazie Slater
- McAfee & Taft
- McGlinchey Stafford
- Milbank LLP
- Minor Johnston
- Mitchell Williams
- Montgomery McCracken
- Morrison Mahoney
- Much Shelist
- Murphy & King
- Murray Law Firm
- Myers Doyle
- Nixon Peabody
- Obermayer Rebmann
- Ogletree Deakins
- Perkins Coie
- Perry Krumsiek
- Phillips Murrah
- Pogust Goodhead
- Porter Wright
- Provost Umphrey
- Ramunno & Ramunno
- Randall & Schumacher
- Reed Smith
- Robins Kaplan
- Robinson Brog
- Robinson Calcagnie
- Ropes & Gray
- Rush Hannula
- Schroeter Goldmark
- Seeger Weiss
- Shaheen & Gordon
- Shapiro Haber
- Shook Hardy
- Sidley Austin
- Skadden Arps
- Snapka Law Firm
- Sommers Schwartz
- Spector Roseman
- Stinson LLP
- Stites & Harbison
- Taylor Martino
- Todd & Weld
- Trammell PC
- Verrill Dana
- Wallace Jordan
- Watkins & Eager
- Weil Gotshal
- Weisman Kennedy
- West & Rosa
- Wheeler Trigg
- White and Williams
- Williams Kastner
- Williams Porter Day & Neville
- WilmerHale
- Wright & Greenhill
- Zimmerman Reed
Companies
- Aetna Inc.
- Allergan PLC
- American Home Assurance Co.
- Assurant Inc.
- Berkshire Hathaway GUARD Insurance Cos.
- BlueCross BlueShield of Massachusetts
- Blue Cross & Blue Shield of Minnesota
- Excellus BlueCross BlueShield
- Florida Blue
- Glenmark Pharmaceuticals Ltd.
- Guardian Life Insurance Co. of America
- Hertz Global Holdings Inc.
- IMS Health Inc.
- Johnson & Johnson
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- The Travelers Cos. Inc.
- Trustmark Corp.
Sectors & Industries:
-
May 26, 2015
Pfizer MDL Plaintiffs Blast Bernstein Liebhard's Fee Bid
The plaintiffs' steering committee in the multidistrict litigation against Pfizer over its alleged illegal marketing of Neurontin for off-label use told a Massachusetts federal judge Friday that Bernstein Liebhard is seeking more money than it legally deserves.
-
May 08, 2015
Pfizer MDL's $91M Atty Fees Misallocated, Firm Says
Bernstein Liebhard LLP told a Massachusetts federal judge Thursday that the plaintiffs' steering committee in multidistrict litigation accusing Pfizer Inc. of illegally marketing Neurontin for off-label use was unfairly doling out the $91 million in attorneys' fees from the $325 million settlement pot.
-
November 10, 2014
Attys' Fee Award Cut To $91M In Pfizer Neurontin MDL
A Massachusetts federal judge on Monday awarded $91 million to the plaintiffs attorneys in multidistrict litigation accusing Pfizer Inc. of illegally marketing Neurontin for off-label use, saying the $108 million they requested from the $325 million settlement pot was too high.
-
May 30, 2014
Pfizer To Pay $325M To End Neurontin Off-Label Suit
Pfizer Inc. and Warner-Lambert Co. LLC have agreed to pay $325 million to a class of third-party payers who bought the drug Neurontin to settle allegations that they fraudulently marketed the medicine, according to documents filed in Massachusetts federal court on Friday.
-
April 17, 2014
Pfizer, Kaiser End Neurontin Off-Label Suit With Fee Deal
Pfizer Inc. agreed on Wednesday to settle the remaining claims for attorneys' fees in Kaiser Foundation Health Plan Inc.'s suit against the drugmaker in multidistrict litigation over the allegedly deceptive marketing of Neurontin, after the First Circuit determined that the off-label prescriptions harmed Kaiser and others.
-
May 18, 2011
Neurontin Judge Won't Certify 3rd-Party Bipolar Class
A Massachusetts judge in charge of the multidistrict litigation over Pfizer Inc.'s Neurontin refused again Tuesday to certify a subclass of third-party payors accusing the drug giant of fraudulently promoting the epilepsy drug to treat bipolar disorder.
-
April 20, 2011
Aetna Loses Bid To Re-Enter Pfizer Off-Label MDL
A Massachusetts judge on Wednesday refused to reconsider Aetna Inc.'s suit accusing Pfizer Inc. of improperly marketing the epilepsy drug Neurontin in violation of racketeering and competition laws.
-
April 05, 2011
166 Plaintiffs Tossed From Neurontin MDL
In a multidistrict litigation accusing Pfizer Inc. and Warner-Lambert Co. LLC of off-label marketing of epilepsy drug Neurontin, a Massachusetts federal judge on Tuesday dismissed 166 plaintiffs in three lawsuits brought by attorney Levi Boone, citing repeated discovery failures.
-
December 10, 2010
Blue Cross, Others Booted In Pfizer Neurontin MDL
A judge on Friday threw out the bulk of claims brought by consumers, insurers and others in a consolidated class action alleging Pfizer Inc. and Warner-Lambert Co. fraudulently marketed the drug Neurontin for off-label use, ruling that they failed to establish causation.
-
September 18, 2009
Pfizer Accuses Expert Of Tainting Doctor Testimony
Pfizer Inc. is urging a federal court overseeing the multidistrict litigation over its alleged off-label promotion of epilepsy drug Neurontin to issue an order preventing plaintiffs’ counsel and their experts from allegedly trying to tamper with the testimony of plaintiffs’ doctors.